Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results
November 12, 2015 7:01 AM ESTCOPENHAGEN, Denmark, Nov. 12, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and nine months ended September 30, 2015.
Ascendis Pharma reported a cash balance of 128.2 million at September 30, 2015.
"Our recent Phase 2 pediatric study presentation at the 54th Annual Meeting of the European Society of Pediatric Endocrinology confirmed once-weekly TransCon Growth Hormone's attractive profile to a large, international clinically-focused audience," stated Jan Mikkelsen, President and Chief Executive Officer of... More
Ascendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference
November 11, 2015 4:05 PM ESTCOPENHAGEN, Denmark, Nov. 11, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at an upcoming investor conference.
Event:... More
